The global gene therapy market was valued at $393.35 million in 2018, and is estimated to reach $6,205.85 million by 2026, registering a CAGR of 34.8% from 2019 to 2026. Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patient’s cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.
Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is on an increase, despite the limited number of products that have successfully reached the market. In addition, benefits of gene therapy over conventional cancer therapies and increase in government support fuel the growth of the gene therapy market.
The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market. On the contrary, increase in the pipeline developments for gene therapy market are expected to provide lucrative opportunity during the forecast period.
The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key MARKET BENEFITS FOR STAKEHOLDERS
By Vector Type
Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is on an increase, despite the limited number of products that have successfully reached the market. In addition, benefits of gene therapy over conventional cancer therapies and increase in government support fuel the growth of the gene therapy market.
The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market. On the contrary, increase in the pipeline developments for gene therapy market are expected to provide lucrative opportunity during the forecast period.
The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key MARKET BENEFITS FOR STAKEHOLDERS
- This report offers a detailed quantitative analysis of the current market trends from 2018 to 2026 to identify the prevailing opportunities.
- The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
- In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
- The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
By Vector Type
- Viral vector
- Retroviruses
- Lentiviruses
- Adenoviruses
- Adeno Associated Virus
- Herpes Simplex Virus
- Poxvirus
- Vaccinia Virus
- Others
- Non-viral vector
- Naked/Plasmid Vectors
- Gene Gun
- Electroporation
- Lipofection
- Others
- Antigen
- Cytokine
- Tumor Suppressor
- Suicide
- Deficiency
- Growth factors
- Receptors
- Others
- Oncological Disorders
- Rare Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Infectious disease
- Other Diseases
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
- Adaptimmune Therapeutics Plc.
- Anchiano Therapeutics Ltd.
- Achieve Life Sciences, Inc.
- Adverum Biotechnologies, Inc.
- Abeona Therapeutics Inc.
- Applied Genetic Technologies Corporation
- Arbutus Biopharma Corporation,
- Audentes Therapeutics, Inc.
- AveXis, Inc.
- Bluebird Bio, Inc.
- Celgene Corporation
- CRISPR Therapeutics AG
- Editas Medicine, Inc.
- Editas Medicine, Inc.
- GlaxoSmithKline Plc.
- Intellia Therapeutics, Inc.
- Merck & Co., Inc.
- Novartis AG
- REGENXBIO Inc.
- Spark Therapeutics, Inc.
- Sangamo Therapeutics, Inc.
- Uniqure N. V.
- Voyager Therapeutics, Inc
- Amgen
- Epeius Biotechnologies
- Sanofi
- Juno Therapeutics
- Advantagene
Note: Product cover images may vary from those shown
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. CXO Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Top Player Positioning, 2018
3.4. Porter’S Five Forces Analysis
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. High Investment For R&D Activities Pertaining To Gene Therapy
3.5.1.2. Increase In Prevalence of Cancer
3.5.1.3. Growth In Awareness Regarding Gene Therapy
3.5.2. Restraints
3.5.2.1. High Cost Associated With Gene Therapies
3.5.2.2. Unwanted Immune Responses
3.5.3. Opportunities
3.5.3.1. Untapped Potential For Emerging Markets
Chapter 4: Gene Therapy Market, By Vector Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Viral Vectors
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Size And Forecast, By Type
4.2.4. Market Size And Forecast, By Country
4.2.5. Adenovirus
4.2.6. Lentivirus
4.2.7. Retrovirus
4.2.8. Adeno-Associated Virus
4.2.9. Herpes Simplex Virus
4.2.10. Poxvirus
4.2.11. Vaccinia Virus
4.2.12. Others
4.3. Non-Viral Techniques
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Size And Forecast, By Type
4.3.4. Market Size And Forecast, By Country
4.3.5. Naked Plasmid Vector
4.3.6. Gene Gun
4.3.7. Electroporation
4.3.8. Lipofection
4.3.9. Others
Chapter 5: Gene Therapy Market, By Gene Type
5.1. Overview
5.1.1. Market Size And Forecast, Type
5.2. Antigen
5.2.1. Market Size And Forecast
5.2.2. Market Size And Forecast, By Country
5.3. Cytokine
5.3.1. Market Size And Forecast
5.3.2. Market Size And Forecast, By Country
5.4. Tumor Suppressor
5.4.1. Market Size And Forecast, By Region
5.4.2. Market Size And Forecast, By Country
5.5. Suicide Gene
5.5.1. Market Size And Forecast
5.5.2. Market Size And Forecast, By Country
5.6. Deficiency
5.6.1. Market Size And Forecast, By Region
5.6.2. Market Size And Forecast, By Country
5.7. Growth Factors
5.7.1. Market Size And Forecast, By Region
5.7.2. Market Size And Forecast, By Country
5.8. Receptors
5.8.1. Market Size And Forecast, By Region
5.8.2. Market Size And Forecast, By Country
5.9. Others
5.9.1. Market Size And Forecast, By Region
5.9.2. Market Size And Forecast, By Country
Chapter 6: Gene Therapy Market, By Application
6.1. Overview
6.1.1. Market Size And Forecast, By Application
6.2. Oncological Disorders
6.2.1. Market Size And Forecast, By Region
6.2.2. Market Size And Forecast, By Country
6.3. Rare Diseases
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Size And Forecast, By Country
6.4. Cardiovascular Diseases
6.4.1. Market Size And Forecast, By Region
6.4.2. Market Size And Forecast, By Country
6.5. Neurological Disorders
6.5.1. Market Size And Forecast
6.5.2. Market Size And Forecast, By Country
6.6. Infectious Diseases
6.6.1. Market Size And Forecast, By Region
6.6.2. Market Size And Forecast, By Country
6.7. Other Diseases
6.7.1. Market Size And Forecast
6.7.2. Market Size And Forecast, By Country
Chapter 7: Gene Therapy Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends, Growth Factors, And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.3. Market Size And Forecast, By Vector Type
7.2.4. Market Size And Forecast, By Gene Type
7.2.5. Market Size And Forecast, By Application
7.2.5.1. U.S. Market Size And Forecast, By Vector Type
7.2.5.2. U.S. Market Size And Forecast, By Gene Type
7.2.5.3. U.S. Market Size And Forecast, By Application
7.2.5.4. Canada Market Size And Forecast, By Vector Type
7.2.5.5. Canada Market Size And Forecast, By Gene Type
7.2.5.6. Canada Market Size And Forecast, By Application
7.2.5.7. Mexico Market Size And Forecast, By Vector Type
7.2.5.8. Mexico Market Size And Forecast, By Gene Type
7.2.5.9. Mexico Market Size And Forecast, By Application
7.3. Europe
7.3.1. Key Market Trends, Growth Factors, And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.3. Market Size And Forecast, By Vector Type
7.3.4. Market Size And Forecast, By Gene Type
7.3.5. Market Size And Forecast, By Application
7.3.5.1. Germany Market Size And Forecast, By Vector Type
7.3.5.2. Germany Market Size And Forecast, By Gene Type
7.3.5.3. Germany Market Size And Forecast, By Application
7.3.5.4. France Market Size And Forecast, By Vector Type
7.3.5.5. France Market Size And Forecast, By Gene Type
7.3.5.6. France Market Size And Forecast, By Application
7.3.5.7. UK Market Size And Forecast, By Vector Type
7.3.5.8. UK Market Size And Forecast, By Gene Type
7.3.5.9. UK Market Size And Forecast, By Application
7.3.5.10. Italy Market Size And Forecast, By Vector Type
7.3.5.11. Italy Market Size And Forecast, By Gene Type
7.3.5.12. Italy Market Size And Forecast, By Application
7.3.5.13. Spain Market Size And Forecast, By Vector Type
7.3.5.14. Spain Market Size And Forecast, By Gene Type
7.3.5.15. Spain Market Size And Forecast, By Application
7.3.5.16. Rest of Europe Market Size And Forecast, By Vector Type
7.3.5.17. Rest of Europe Market Size And Forecast, By Gene Type
7.3.5.18. Rest of Europe Market Size And Forecast, By Application
7.4. Asia-Pacific
7.4.1. Key Market Trends, Growth Factors, And Opportunities
7.4.2. Market Size And Forecast, By Country
7.4.3. Market Size And Forecast, By Vector Type
7.4.4. Market Size And Forecast, By Gene Type
7.4.5. Market Size And Forecast, By Application
7.4.5.1. Japan Market Size And Forecast, By Vector Type
7.4.5.2. Japan Market Size And Forecast, By Gene Type
7.4.5.3. Japan Market Size And Forecast, By Application
7.4.5.4. China Market Size And Forecast, By Vector Type
7.4.5.5. China Market Size And Forecast, By Gene Type
7.4.5.6. China Market Size And Forecast, By Application
7.4.5.7. India Market Size And Forecast, By Vector Type
7.4.5.8. India Market Size And Forecast, By Gene Type
7.4.5.9. India Market Size And Forecast, By Application
7.4.5.10. South Korea Market Size And Forecast, By Vector Type
7.4.5.11. South Korea Market Size And Forecast, By Gene Type
7.4.5.12. South Korea Market Size And Forecast, By Application
7.4.5.13. Rest of Asia-Pacific Market Size And Forecast, By Vector Type
7.4.5.14. Rest of Asia-Pacific Market Size And Forecast, By Gene Type
7.4.5.15. Rest of Asia-Pacific Market Size And Forecast, By Application
7.5. LAMEA
7.5.1. Key Market Trends, Growth Factors, And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.3. Market Size And Forecast, By Vector Type
7.5.4. Market Size And Forecast, By Gene Type
7.5.5. Market Size And Forecast, By Application
7.5.5.1. Brazil Market Size And Forecast, By Vector Type
7.5.5.2. Brazil Market Size And Forecast, By Gene Type
7.5.5.3. Brazil Market Size And Forecast, By Application
7.5.5.4. South Africa Market Size And Forecast, By Vector Type
7.5.5.5. South Africa Market Size And Forecast, By Gene Type
7.5.5.6. South Africa Market Size And Forecast, By Application
7.5.5.7. Rest of LAMEA Market Size And Forecast, By Vector Type
7.5.5.8. Rest of LAMEA Market Size And Forecast, By Gene Type
7.5.5.9. Rest of LAMEA Market Size And Forecast, By Application
Chapter 8: Company Profile
8.1. Adaptimmune Therapeutics Plc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves And Developments
8.2. Anchiano Therapeutics Ltd.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.3. Achieve Life Sciences, Inc.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Key Strategic Moves And Developments
8.4. Adverum Biotechnologies, Inc.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Key Strategic Moves And Developments
8.5. Abeona Therapeutics Inc.
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves And Developments
8.6. Applied Genetic Technologies Corporation
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments
8.7. Arbutus Biopharma Corporation
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Product Portfolio
8.7.4. Business Performance
8.7.5. Key Strategic Moves And Developments
8.8. Audentes Therapeutics Inc.
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Product Portfolio
8.8.4. Key Strategic Moves And Developments
8.9. Avexis Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Product Portfolio
8.9.4. Key Strategic Moves And Developments
8.10. Bluebird Bio, Inc.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves And Developments
8.11. Celgene Corporation
8.11.1. Company Overview
8.11.2. Company Snapshot
8.11.3. Operating Business Segments
8.11.4. Product Portfolio
8.11.5. Business Performance
8.11.6. Key Strategic Moves And Developments
8.12. Crispr Therapeutics Ag
8.12.1. Company Overview
8.12.2. Company Snapshot
8.12.3. Product Portfolio
8.12.4. Business Performance
8.12.5. Key Strategic Moves And Developments
8.13. Editas Medicine, Inc.
8.13.1. Company Overview
8.13.2. Company Snapshot
8.13.3. Operating Business Segments
8.13.4. Product Portfolio
8.13.5. Business Performance
8.13.6. Key Strategic Moves And Developments
8.14. Gilead Sciences, Inc.
8.14.1. Company Overview
8.14.2. Company Snapshot
8.14.3. Operating Business Segments
8.14.4. Product Portfolio
8.14.5. Business Performance
8.14.6. Key Strategic Moves And Developments
8.15. Glaxosmithkline Plc
8.15.1. Company Overview
8.15.2. Company Snapshot
8.15.3. Operating Business Segments
8.15.4. Product Portfolio
8.15.5. Business Performance
8.15.6. Key Strategic Moves And Developments
8.16. Intellia Therapeutics Inc.
8.16.1. Company Overview
8.16.2. Company Snapshot
8.16.3. Operating Business Segments
8.16.4. Product Portfolio
8.16.5. Business Performance
8.16.6. Key Strategic Moves And Developments
8.17. Merck & Co., Inc.
8.17.1. Company Overview
8.17.2. Company Snapshot
8.17.3. Operating Business Segments
8.17.4. Product Portfolio
8.17.5. Business Performance
8.17.6. Key Strategic Moves And Developments
8.18. Novartis Ag
8.18.1. Company Overview
8.18.2. Company Snapshot
8.18.3. Operating Business Segments
8.18.4. Product Portfolio
8.18.5. Business Performance
8.18.6. Key Strategic Moves And Developments
8.19. Regenxbio, Inc.
8.19.1. Company Overview
8.19.2. Company Snapshot
8.19.3. Product Portfolio
8.19.4. Business Performance
8.19.5. Key Strategic Moves And Developments
8.20. Spark Therapeutics, Inc.
8.20.1. Company Overview
8.20.2. Company Snapshot
8.20.3. Operating Business Segments
8.20.4. Product Portfolio
8.20.5. Business Performance
8.20.6. Key Strategic Moves And Developments
8.21. Sangamo Therapeutics, Inc.
8.21.1. Company Overview
8.21.2. Company Snapshot
8.21.3. Operating Business Segments
8.21.4. Product Portfolio
8.21.5. Business Performance
8.21.6. Key Strategic Moves And Developments
8.22. Uniqure N. V.
8.22.1. Company Overview
8.22.2. Company Snapshot
8.22.3. Operation Segments
8.22.4. Product Portfolio
8.22.5. Business Performance
8.22.6. Key Strategic Moves And Developments
8.23. Voyager Therapeutics, Inc.
8.23.1. Company Overview
8.23.2. Company Snapshot
8.23.3. Operating Business Segments
8.23.4. Product Portfolio
8.23.5. Business Performance
8.23.6. Key Strategic Moves And Developments
1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. CXO Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Top Player Positioning, 2018
3.4. Porter’S Five Forces Analysis
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. High Investment For R&D Activities Pertaining To Gene Therapy
3.5.1.2. Increase In Prevalence of Cancer
3.5.1.3. Growth In Awareness Regarding Gene Therapy
3.5.2. Restraints
3.5.2.1. High Cost Associated With Gene Therapies
3.5.2.2. Unwanted Immune Responses
3.5.3. Opportunities
3.5.3.1. Untapped Potential For Emerging Markets
Chapter 4: Gene Therapy Market, By Vector Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Viral Vectors
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Size And Forecast, By Type
4.2.4. Market Size And Forecast, By Country
4.2.5. Adenovirus
4.2.6. Lentivirus
4.2.7. Retrovirus
4.2.8. Adeno-Associated Virus
4.2.9. Herpes Simplex Virus
4.2.10. Poxvirus
4.2.11. Vaccinia Virus
4.2.12. Others
4.3. Non-Viral Techniques
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Size And Forecast, By Type
4.3.4. Market Size And Forecast, By Country
4.3.5. Naked Plasmid Vector
4.3.6. Gene Gun
4.3.7. Electroporation
4.3.8. Lipofection
4.3.9. Others
Chapter 5: Gene Therapy Market, By Gene Type
5.1. Overview
5.1.1. Market Size And Forecast, Type
5.2. Antigen
5.2.1. Market Size And Forecast
5.2.2. Market Size And Forecast, By Country
5.3. Cytokine
5.3.1. Market Size And Forecast
5.3.2. Market Size And Forecast, By Country
5.4. Tumor Suppressor
5.4.1. Market Size And Forecast, By Region
5.4.2. Market Size And Forecast, By Country
5.5. Suicide Gene
5.5.1. Market Size And Forecast
5.5.2. Market Size And Forecast, By Country
5.6. Deficiency
5.6.1. Market Size And Forecast, By Region
5.6.2. Market Size And Forecast, By Country
5.7. Growth Factors
5.7.1. Market Size And Forecast, By Region
5.7.2. Market Size And Forecast, By Country
5.8. Receptors
5.8.1. Market Size And Forecast, By Region
5.8.2. Market Size And Forecast, By Country
5.9. Others
5.9.1. Market Size And Forecast, By Region
5.9.2. Market Size And Forecast, By Country
Chapter 6: Gene Therapy Market, By Application
6.1. Overview
6.1.1. Market Size And Forecast, By Application
6.2. Oncological Disorders
6.2.1. Market Size And Forecast, By Region
6.2.2. Market Size And Forecast, By Country
6.3. Rare Diseases
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Size And Forecast, By Country
6.4. Cardiovascular Diseases
6.4.1. Market Size And Forecast, By Region
6.4.2. Market Size And Forecast, By Country
6.5. Neurological Disorders
6.5.1. Market Size And Forecast
6.5.2. Market Size And Forecast, By Country
6.6. Infectious Diseases
6.6.1. Market Size And Forecast, By Region
6.6.2. Market Size And Forecast, By Country
6.7. Other Diseases
6.7.1. Market Size And Forecast
6.7.2. Market Size And Forecast, By Country
Chapter 7: Gene Therapy Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends, Growth Factors, And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.3. Market Size And Forecast, By Vector Type
7.2.4. Market Size And Forecast, By Gene Type
7.2.5. Market Size And Forecast, By Application
7.2.5.1. U.S. Market Size And Forecast, By Vector Type
7.2.5.2. U.S. Market Size And Forecast, By Gene Type
7.2.5.3. U.S. Market Size And Forecast, By Application
7.2.5.4. Canada Market Size And Forecast, By Vector Type
7.2.5.5. Canada Market Size And Forecast, By Gene Type
7.2.5.6. Canada Market Size And Forecast, By Application
7.2.5.7. Mexico Market Size And Forecast, By Vector Type
7.2.5.8. Mexico Market Size And Forecast, By Gene Type
7.2.5.9. Mexico Market Size And Forecast, By Application
7.3. Europe
7.3.1. Key Market Trends, Growth Factors, And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.3. Market Size And Forecast, By Vector Type
7.3.4. Market Size And Forecast, By Gene Type
7.3.5. Market Size And Forecast, By Application
7.3.5.1. Germany Market Size And Forecast, By Vector Type
7.3.5.2. Germany Market Size And Forecast, By Gene Type
7.3.5.3. Germany Market Size And Forecast, By Application
7.3.5.4. France Market Size And Forecast, By Vector Type
7.3.5.5. France Market Size And Forecast, By Gene Type
7.3.5.6. France Market Size And Forecast, By Application
7.3.5.7. UK Market Size And Forecast, By Vector Type
7.3.5.8. UK Market Size And Forecast, By Gene Type
7.3.5.9. UK Market Size And Forecast, By Application
7.3.5.10. Italy Market Size And Forecast, By Vector Type
7.3.5.11. Italy Market Size And Forecast, By Gene Type
7.3.5.12. Italy Market Size And Forecast, By Application
7.3.5.13. Spain Market Size And Forecast, By Vector Type
7.3.5.14. Spain Market Size And Forecast, By Gene Type
7.3.5.15. Spain Market Size And Forecast, By Application
7.3.5.16. Rest of Europe Market Size And Forecast, By Vector Type
7.3.5.17. Rest of Europe Market Size And Forecast, By Gene Type
7.3.5.18. Rest of Europe Market Size And Forecast, By Application
7.4. Asia-Pacific
7.4.1. Key Market Trends, Growth Factors, And Opportunities
7.4.2. Market Size And Forecast, By Country
7.4.3. Market Size And Forecast, By Vector Type
7.4.4. Market Size And Forecast, By Gene Type
7.4.5. Market Size And Forecast, By Application
7.4.5.1. Japan Market Size And Forecast, By Vector Type
7.4.5.2. Japan Market Size And Forecast, By Gene Type
7.4.5.3. Japan Market Size And Forecast, By Application
7.4.5.4. China Market Size And Forecast, By Vector Type
7.4.5.5. China Market Size And Forecast, By Gene Type
7.4.5.6. China Market Size And Forecast, By Application
7.4.5.7. India Market Size And Forecast, By Vector Type
7.4.5.8. India Market Size And Forecast, By Gene Type
7.4.5.9. India Market Size And Forecast, By Application
7.4.5.10. South Korea Market Size And Forecast, By Vector Type
7.4.5.11. South Korea Market Size And Forecast, By Gene Type
7.4.5.12. South Korea Market Size And Forecast, By Application
7.4.5.13. Rest of Asia-Pacific Market Size And Forecast, By Vector Type
7.4.5.14. Rest of Asia-Pacific Market Size And Forecast, By Gene Type
7.4.5.15. Rest of Asia-Pacific Market Size And Forecast, By Application
7.5. LAMEA
7.5.1. Key Market Trends, Growth Factors, And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.3. Market Size And Forecast, By Vector Type
7.5.4. Market Size And Forecast, By Gene Type
7.5.5. Market Size And Forecast, By Application
7.5.5.1. Brazil Market Size And Forecast, By Vector Type
7.5.5.2. Brazil Market Size And Forecast, By Gene Type
7.5.5.3. Brazil Market Size And Forecast, By Application
7.5.5.4. South Africa Market Size And Forecast, By Vector Type
7.5.5.5. South Africa Market Size And Forecast, By Gene Type
7.5.5.6. South Africa Market Size And Forecast, By Application
7.5.5.7. Rest of LAMEA Market Size And Forecast, By Vector Type
7.5.5.8. Rest of LAMEA Market Size And Forecast, By Gene Type
7.5.5.9. Rest of LAMEA Market Size And Forecast, By Application
Chapter 8: Company Profile
8.1. Adaptimmune Therapeutics Plc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves And Developments
8.2. Anchiano Therapeutics Ltd.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.3. Achieve Life Sciences, Inc.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Key Strategic Moves And Developments
8.4. Adverum Biotechnologies, Inc.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Key Strategic Moves And Developments
8.5. Abeona Therapeutics Inc.
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves And Developments
8.6. Applied Genetic Technologies Corporation
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments
8.7. Arbutus Biopharma Corporation
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Product Portfolio
8.7.4. Business Performance
8.7.5. Key Strategic Moves And Developments
8.8. Audentes Therapeutics Inc.
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Product Portfolio
8.8.4. Key Strategic Moves And Developments
8.9. Avexis Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Product Portfolio
8.9.4. Key Strategic Moves And Developments
8.10. Bluebird Bio, Inc.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves And Developments
8.11. Celgene Corporation
8.11.1. Company Overview
8.11.2. Company Snapshot
8.11.3. Operating Business Segments
8.11.4. Product Portfolio
8.11.5. Business Performance
8.11.6. Key Strategic Moves And Developments
8.12. Crispr Therapeutics Ag
8.12.1. Company Overview
8.12.2. Company Snapshot
8.12.3. Product Portfolio
8.12.4. Business Performance
8.12.5. Key Strategic Moves And Developments
8.13. Editas Medicine, Inc.
8.13.1. Company Overview
8.13.2. Company Snapshot
8.13.3. Operating Business Segments
8.13.4. Product Portfolio
8.13.5. Business Performance
8.13.6. Key Strategic Moves And Developments
8.14. Gilead Sciences, Inc.
8.14.1. Company Overview
8.14.2. Company Snapshot
8.14.3. Operating Business Segments
8.14.4. Product Portfolio
8.14.5. Business Performance
8.14.6. Key Strategic Moves And Developments
8.15. Glaxosmithkline Plc
8.15.1. Company Overview
8.15.2. Company Snapshot
8.15.3. Operating Business Segments
8.15.4. Product Portfolio
8.15.5. Business Performance
8.15.6. Key Strategic Moves And Developments
8.16. Intellia Therapeutics Inc.
8.16.1. Company Overview
8.16.2. Company Snapshot
8.16.3. Operating Business Segments
8.16.4. Product Portfolio
8.16.5. Business Performance
8.16.6. Key Strategic Moves And Developments
8.17. Merck & Co., Inc.
8.17.1. Company Overview
8.17.2. Company Snapshot
8.17.3. Operating Business Segments
8.17.4. Product Portfolio
8.17.5. Business Performance
8.17.6. Key Strategic Moves And Developments
8.18. Novartis Ag
8.18.1. Company Overview
8.18.2. Company Snapshot
8.18.3. Operating Business Segments
8.18.4. Product Portfolio
8.18.5. Business Performance
8.18.6. Key Strategic Moves And Developments
8.19. Regenxbio, Inc.
8.19.1. Company Overview
8.19.2. Company Snapshot
8.19.3. Product Portfolio
8.19.4. Business Performance
8.19.5. Key Strategic Moves And Developments
8.20. Spark Therapeutics, Inc.
8.20.1. Company Overview
8.20.2. Company Snapshot
8.20.3. Operating Business Segments
8.20.4. Product Portfolio
8.20.5. Business Performance
8.20.6. Key Strategic Moves And Developments
8.21. Sangamo Therapeutics, Inc.
8.21.1. Company Overview
8.21.2. Company Snapshot
8.21.3. Operating Business Segments
8.21.4. Product Portfolio
8.21.5. Business Performance
8.21.6. Key Strategic Moves And Developments
8.22. Uniqure N. V.
8.22.1. Company Overview
8.22.2. Company Snapshot
8.22.3. Operation Segments
8.22.4. Product Portfolio
8.22.5. Business Performance
8.22.6. Key Strategic Moves And Developments
8.23. Voyager Therapeutics, Inc.
8.23.1. Company Overview
8.23.2. Company Snapshot
8.23.3. Operating Business Segments
8.23.4. Product Portfolio
8.23.5. Business Performance
8.23.6. Key Strategic Moves And Developments
Note: Product cover images may vary from those shown
According to the report titled, 'Gene Therapy Market by Vector Type, Gene Type, and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026', the gene therapy market size was $393.35 million in 2018, and is estimated to reach $6,205.85 million by 2026, registering a CAGR of 34.8% from 2019 to 2026.
Gene therapies are promising therapies applicable to a broad range of diseases; their aim is to radically treat the causes of the diseases instead of only relieving the symptoms. They may be effective on a wide range of previously untreated diseases, such as hematological, ocular, neurodegenerative diseases, and several cancers. For example, adeno associated AAV2 vectors carrying the therapeutic gene (RPE65) intra-retinal injection resulted in improved vision for people with Leber’s Congenital Amaurosis. Gene therapies can be applied either in combination with cell products and through an ex vivo treatment mode (e.g. Strimvelis), or directly administered in vitro (e.g. Glybera). Several vectors present clinically relevant options, including adenovirus (AV), adeno-associated virus (AAV), and lentivirus.
The increase in funding for R&D activities pertaining to gene therapy and increase in awareness regarding gene therapy are the major factors that drive the gene therapy market growth. In addition, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in prevalence of cancer can fuel the growth of the gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to hamper the growth of the gene therapy market.
Among the vector type, non-viral vector is anticipated to be a lucrative in the global gene therapy market, due to the technological advancements such as physicochemical approaches that includes material such as lipid, naked DNA, chromosomes, plasmid, cationic polymers, and conjugate complexes of these vectors with positive results for these therapies during the preclinical and clinical trials for the treatment of various diseases.
Among the gene type, antigen dominates the overall market accounting for two-ninths of the global gene therapy market share in 2018. Among the applications, oncological disorders segment is the largest contributor towards the growth of the gene therapy market, owing to due to the availability of many gene therapy products that can be used to treat cancer and large patient population base. In addition, there are large number of gene therapies undergoing clinical trials for cancer and cardiovascular diseases.
In 2018, North America accounted for maximum contribution to the total revenue generated, and is anticipated to continue this gene therapy market trends during the forecast period. This is attributed to the high prevalence rate of cancer, presence of high disposable income, and high funding for R&D activities associated with gene therapy. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period owing to rise in incidence rate of cancer, increase in government initiative to improve healthcare infrastructure, and rise in healthcare expenditure.
Key Findings of the Gene Therapy Market:
Non-viral vectors segment is projected to grow at the highest rate with the CAGR of 34.6% during the analysis period.
Oncological disorders segment generated the highest revenue, and is expected to continue its dominance in future in the global gene therapy market.
Asia-Pacific is projected to grow at the fasted CAGR during the forecast period.
China is expected to grow highest in the Asia-Pacific region during the forecast period.
Tumor suppressor is the expected to grow fastest during the forecast period.
The report provides a comprehensive analysis of the key players operating in the global gene therapy market industry, namely Adaptimmune Therapeutics Plc., Anchiano Therapeutics Ltd., Achieve Life Sciences, Inc., Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Arbutus Biopharma Corporation, Audentes Therapeutics, Inc., AveXis, Inc., Bluebird Bio, Inc., Celgene Corporation, CRISPR Therapeutics AG, Editas Medicine, Inc., Editas Medicine, Inc., GlaxoSmithKline Plc., Intellia Therapeutics, Inc., Merck & Co., Inc., Novartis AG, REGENXBIO Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Inc., Uniqure N. V., Voyager Therapeutics, Inc.
Other prominent players in the value chain (companies not profiled in the report) includes Amgen, Epeius Biotechnologies, Sanofi, Juno Therapeutics, and Advantagene.
Gene therapies are promising therapies applicable to a broad range of diseases; their aim is to radically treat the causes of the diseases instead of only relieving the symptoms. They may be effective on a wide range of previously untreated diseases, such as hematological, ocular, neurodegenerative diseases, and several cancers. For example, adeno associated AAV2 vectors carrying the therapeutic gene (RPE65) intra-retinal injection resulted in improved vision for people with Leber’s Congenital Amaurosis. Gene therapies can be applied either in combination with cell products and through an ex vivo treatment mode (e.g. Strimvelis), or directly administered in vitro (e.g. Glybera). Several vectors present clinically relevant options, including adenovirus (AV), adeno-associated virus (AAV), and lentivirus.
The increase in funding for R&D activities pertaining to gene therapy and increase in awareness regarding gene therapy are the major factors that drive the gene therapy market growth. In addition, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in prevalence of cancer can fuel the growth of the gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to hamper the growth of the gene therapy market.
Among the vector type, non-viral vector is anticipated to be a lucrative in the global gene therapy market, due to the technological advancements such as physicochemical approaches that includes material such as lipid, naked DNA, chromosomes, plasmid, cationic polymers, and conjugate complexes of these vectors with positive results for these therapies during the preclinical and clinical trials for the treatment of various diseases.
Among the gene type, antigen dominates the overall market accounting for two-ninths of the global gene therapy market share in 2018. Among the applications, oncological disorders segment is the largest contributor towards the growth of the gene therapy market, owing to due to the availability of many gene therapy products that can be used to treat cancer and large patient population base. In addition, there are large number of gene therapies undergoing clinical trials for cancer and cardiovascular diseases.
In 2018, North America accounted for maximum contribution to the total revenue generated, and is anticipated to continue this gene therapy market trends during the forecast period. This is attributed to the high prevalence rate of cancer, presence of high disposable income, and high funding for R&D activities associated with gene therapy. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period owing to rise in incidence rate of cancer, increase in government initiative to improve healthcare infrastructure, and rise in healthcare expenditure.
Key Findings of the Gene Therapy Market:
Non-viral vectors segment is projected to grow at the highest rate with the CAGR of 34.6% during the analysis period.
Oncological disorders segment generated the highest revenue, and is expected to continue its dominance in future in the global gene therapy market.
Asia-Pacific is projected to grow at the fasted CAGR during the forecast period.
China is expected to grow highest in the Asia-Pacific region during the forecast period.
Tumor suppressor is the expected to grow fastest during the forecast period.
The report provides a comprehensive analysis of the key players operating in the global gene therapy market industry, namely Adaptimmune Therapeutics Plc., Anchiano Therapeutics Ltd., Achieve Life Sciences, Inc., Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Arbutus Biopharma Corporation, Audentes Therapeutics, Inc., AveXis, Inc., Bluebird Bio, Inc., Celgene Corporation, CRISPR Therapeutics AG, Editas Medicine, Inc., Editas Medicine, Inc., GlaxoSmithKline Plc., Intellia Therapeutics, Inc., Merck & Co., Inc., Novartis AG, REGENXBIO Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Inc., Uniqure N. V., Voyager Therapeutics, Inc.
Other prominent players in the value chain (companies not profiled in the report) includes Amgen, Epeius Biotechnologies, Sanofi, Juno Therapeutics, and Advantagene.
Note: Product cover images may vary from those shown
- Adaptimmune Therapeutics Plc.
- Anchiano Therapeutics Ltd.
- Achieve Life Sciences Inc.
- Adverum Biotechnologies Inc.
- Abeona Therapeutics Inc.
- Applied Genetic Technologies Corporation
- Arbutus Biopharma Corporation
- Audentes Therapeutics
Note: Product cover images may vary from those shown
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
